The white matter of the brain was once disregarded by scientists as passive tissue and secondary to grey matter, where neurons reside....

We are pleased to share that  Release Therapeutics  has been selected as one of 10 Swiss startups to participate in the 5th Innovation...

The agreement unlocks new potential for the clinical development of the legacy oncology platform, as Release Therapeutics advances its...

We are proud to announce that our latest data on our Encapsulated Cell Therapy for Metachromatic Leukodystrophy (MLD) will be showcased...

We are thrilled to announce that Release Therapeutics has been selected to present at the Emerging Biotech Company Track at Swiss Biotech...

Rare Disease Day isn’t about numbers. It’s about people—the individual and their family whose world is forever shifted by a diagnosis...

The field of lysosomal disorders is making great strides, with breakthroughs in basic science paving the way for potential new...

We are thrilled to announce that  Release Therapeutics  is attending the 21st annual WORLDSymposium ™ on Lysosomal Disease Research held...

Dr. Julien Grogg will Lead the Company's Transition to Clinical Development Building on Promising Primate Study GENEVA, 30 January, 2025...

We are thrilled to introduce Release Tx's Scientific Advisory Board (SAB), which brings together leading experts in leukodystrophies,...

All of us at Release Tx are excited to be participating in the the 134th SICTIC Investor Day at  IMD, Lausanne on 28 November 2024, where...

We’re pleased to announce that Release Therapeutics will be attending Founders’ Evening, organised by Lenz & Staehelin on 20 November at...

We are pleased to announce that Release Tx will participate in the upcoming Cell Press LabLinks Tumor Immunology and Immunotherapy...

Release Therapeutics is pleased to announce our participation in the European Society of Gene and Cell Therapy (ESGCT) Congress that will...

Release Therapeutics is thrilled to announce our participation in FutureHealth Lausanne 2024, which kicks off at the SwissTech Convention...

The funding follows the Company’s first preclinical results in metachromatic leukodystrophy and will be invested in studies in non-human...

We are thrilled to announce our strategic collaboration with Paris Brain Institute to explore the potential of our cutting-edge cell...

Release Tx Announces New CEO, aligning with the company’s recent pivot towards treating genetic disorders of the CNS without gene therapy

Release Therapeutics publishes cutting-edge research in Cell Press

Release Therapeutics' strategic pivot towards treating genetic disorders of the central nervous system without gene therapy.